Cyprotex PLC (CRX.L), a preclinical ADME-Tox services company, Monday said its financial performance for the first 5 months of the year is ahead of expectations driven by strong growth in UK revenues.
In its trading update on profit guidance for the year to December 31, 2015, the company said its Board expects that its full year revenues and profits will exceed current market expectations, despite challenges, particularly in the US operations.
For comments and feedback: editorial@rttnews.com